Palisade Bio to Detail PALI-2108 Progress at Stifel Forum
Event summary
- Palisade Bio executives to present at Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026.
- CEO JD Finley and CMO Mitchell Jones to discuss PALI-2108 clinical development program.
- Focus on ulcerative colitis and Crohn’s disease progress, differentiated profile data, and upcoming milestones.
- Live webcast available on Palisade Bio’s Investors page, replay archived for limited time.
- One-on-one investor meetings scheduled post-presentation.
The big picture
Palisade Bio’s presentation at the Stifel forum underscores the growing emphasis on targeted therapies for inflammatory diseases. The company’s focus on prodrugs positions it within a competitive landscape where differentiation in mechanism and efficacy is critical. With PALI-2108 advancing in key indications, the upcoming data could influence both clinical and commercial strategies in the immunology space.
What we're watching
- Clinical Momentum
- Whether PALI-2108’s differentiated profile can accelerate regulatory approval timelines.
- Market Positioning
- How Palisade Bio’s focus on inflammatory and fibrotic diseases aligns with shifting biopharma priorities.
- Investor Sentiment
- The impact of upcoming milestones on Palisade Bio’s valuation and investor confidence.